Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 12471612)

1.

The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice.

Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, Semenchenko AV, Yashin AI.

Int J Cancer. 2003 Jan 20;103(3):300-5.

PMID:
12471612
2.

The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression.

Baturin DA, Alimova IN, Anisimov VN, Popovich IG, Zabezhinski MA, Provinciali M, Mancini R, Franceschi C.

Neuro Endocrinol Lett. 2001 Dec;22(6):441-7.

PMID:
11781542
3.

[Effect of antidiabetic drug diabenol on parameters of biological age, life span and tumor development in NMRI and HER-2/neu mice].

Popovich IG, Zabezhinskiĭ MA, Egormin PA, Anikin IV, Tyndyk ML, Semenchenko AV, Spasov AA, Anisimov VN.

Adv Gerontol. 2004;15:80-90. Russian.

PMID:
15754958
4.

Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.

Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA.

Cell Cycle. 2010 Jan 1;9(1):188-97. Epub 2010 Jan 22.

5.

Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

Anisimov VN, Khavinson VK, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C.

Int J Cancer. 2002 Sep 1;101(1):7-10.

PMID:
12209581
6.

Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.

Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV.

Bull Exp Biol Med. 2005 Jun;139(6):721-3.

PMID:
16224592
7.

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C.

Exp Gerontol. 2005 Aug-Sep;40(8-9):685-93.

PMID:
16125352
8.

Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice.

Anisimov VN, Popovich IG, Alimova IN, Zabezhinski MA, Semenchenko AV, Yashin AI.

Cancer Lett. 2003 Apr 10;193(1):49-55.

PMID:
12691823
9.

Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice.

Pierpaoli E, Viola V, Barucca A, Orlando F, Galli F, Provinciali M.

Carcinogenesis. 2013 Jun;34(6):1352-60. doi: 10.1093/carcin/bgt064. Epub 2013 Feb 20.

10.

Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.

Provinciali M, Papalini F, Orlando F, Pierpaoli S, Donnini A, Morazzoni P, Riva A, Smorlesi A.

Cancer Res. 2007 Mar 1;67(5):2022-9.

11.

p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.

Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.

Cancer Res. 2006 May 1;66(9):4672-80.

12.

Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.

Campbell MJ, Wollish WS, Lobo M, Esserman LJ.

In Vitro Cell Dev Biol Anim. 2002 Jun;38(6):326-33.

PMID:
12513120
13.

Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.

Anisimov VN, Khavinson VKh, Alimova IN, Semchenko AV, Yashin AI.

Bull Exp Biol Med. 2002 Aug;134(2):187-90.

PMID:
12459848
14.

Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.

Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Ménard S.

Cancer Res. 2005 Feb 1;65(3):1071-8.

15.

Light-at-night-induced circadian disruption, cancer and aging.

Anisimov VN, Vinogradova IA, Panchenko AV, Popovich IG, Zabezhinski MA.

Curr Aging Sci. 2012 Dec;5(3):170-7.

PMID:
23237593
16.

[Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice].

Alimova IN, Bashurin DA, Popovich IG, Zabezhinskiĭ MA, Volkov MA, Provinciali M, Franceschi C, Khavincon BKh, Anisimov VN.

Vopr Onkol. 2002;48(1):57-60. Russian.

PMID:
12101568
17.

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G.

J Immunol. 2000 Nov 1;165(9):5133-42.

18.

Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene.

Rao GN, Ney E, Herbert RA.

Breast Cancer Res Treat. 2000 Dec;64(3):287-96.

PMID:
11200779
19.

Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.

Jacquemart IC, Springs AE, Chen WY.

Int J Oncol. 2009 Feb;34(2):517-28.

PMID:
19148488
20.

HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.

Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR.

J Immunol. 2003 Oct 15;171(8):4054-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk